Fibrinolytic therapy has an expanding role in the treatment of many thromboembolic disorders. Four fibrinolytic drugs are currently marketed: streptokinase, anisoylated plasminogen-streptokinase activator complex, urokinase, and recombinant human tissue-type plasminogen activator. All 4 of these drugs activate the fibrinolytic system by converting plasminogen to the active enzyme, plasmin. Plas...

Rivaroxaban (Xarelto) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders. Rivaroxaban inhibits clot-associated and free FXa activity, and prothrombinase activity, and reduces thrombin generation. In animal models, rivaroxaban prevented venous and arterial thrombosis, and was effective at treating venous throm...

Thrombosis is one of the leading cause of thromboembolic disorders affecting million persons worldwide. Several plants used for the treatment of thromboembolic diseases in different systems of traditional medicine have shown anticoagulant/antithrombotic activity and such plants claimed in the traditional system still remain to be scientifically investigated. The review explored various herbal d...

Some haematological diseases are associated to an increased risk of thromboembolic events. We report a case of paroxysmal nocturnal haemoglobinuria (PNH) in which a cerebrovascular event represented the first clinical manifestation of disease. PNH is associated to thromboembolic events, generally of venous districts often involving unusual locations such as mesenteric vessels, sagittal veins, i...

Received May 2007 Accepted September 2007 INTRODUCTION Priapism (painful erection longer than 6 hours) is an uncommon disease that is almost always due to thromboembolic problems. It may occur at any age. The predisposing factors for priapism include thromboembolic disorders such as sickle cell anemia (SCA, the most common cause), sicklebeta-thalassemia, diseases of the central nervous system a...

thromboembolic disease is a common cause of morbidity and mortality. thrombin plays a key role in thrombotic events and thrombin inhibition represents a therapeutic event for thromboembolic events and has been identified as a target of therapy of its pivotal role in coagulation process. anticoagulation is a major intervention for the management of arterial and venous thromboembolic events. dabi...

Pulmonary hypertension (PH) is a haemodynamic and pathophysiological condition defined as increase in mean pulmonary arterial pressure ≥ 25 mmHg at rest as assessed by right heart catheterization (RHC). It can be due to a primary elevation of pressure in the pulmonary arterial system alone (pulmonary arterial hypertension), or secondary to elevations of pressure in the pulmonary venous and capi...

Bleeding disorders and thromboembolic diseases represent abnormalities of the hemostatic mechanism. As this mechanism is basically a defense device against the loss of blood from the vascular system, any serious breakdown can bring about life-threatening hemorrhages. The author describes the inherent problems involved in these cases; and since many of the recognized congenital and acquired blee...

BACKGROUND AND PURPOSE Factor Xa (FXa) is a key coagulation protease and target for novel antithrombotic agents for prevention and treatment of diverse thromboembolic disorders. In the present study we describe the effect of a novel, potent, and selective FXa inhibitor, DPC602, on brain damage and neurobehavioral consequence in a rat thromboembolic model of stroke. METHODS Thromboembolic stro...